Quintrio
Home

Stock overview

Gelteq Limited Ordinary Shares

GELS

Gelteq Ltd is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, preserving the simplicity, accessibility, and efficacy of oral delivery. Its principal products are edible gels and their application in gel-based dosage forms across pets, sports, pharmaceutical, over-the-counter, and nutraceutical categories, leveraging its patent pending multiple ingredient dosage forms. The company develops and tests gel-based delivery systems for humans and pets and focuses on out-licensing its technology to companies to create products that can be manufactured and sold, while continuing to manufacture existing products under license on a white label basis.

Last trade $0.332
Day change -$0.0269 (-7.50%)
Day range $0.276 – $0.42
Volume 77,239
Market cap $4M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for GELS.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for GELS.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Tumble Ahead Of SC Ruling On Trump's Tariffs— Wells Fargo, BP, WeRide In Focus (UPDATED)

U.S. stock futures declined on Wednesday as investors await a Supreme Court ruling on Trump's tariff authority. The Consumer Price Index rose 2.7% year-over-year in December, matching expectations, while core CPI came in slightly below forecasts at 2.6%. Major indices including the Dow Jones, S&P 500, and Nasdaq 100 all declined in premarket trading. Notable movers include Wells Fargo reporting earnings, BP announcing a $5 billion writedown in energy transition businesses, WeRide launching a robotaxi service on WeChat, and TG Therapeutics providing optimistic 2026 guidance.

GlobeNewswire Inc.

Gelteq Appoints Matthew Jones as Head of Sports Performance

Gelteq Limited, a global biotechnology company, has appointed Matthew Jones as Head of Sports Performance to oversee the growth, outreach, and customer strategy of its sports vertical. Jones, a leading sports dietitian, will focus on expanding the adoption of Gelteq's gel-based delivery platform in the sports industry.

GlobeNewswire Inc.

Gelteq Limited Closes US$5.2 Million Initial Public Offering

Gelteq Limited, a global biotechnology company, announced the closing of its initial public offering of 1,300,000 ordinary shares at a public offering price of US$4.00 per share. The company intends to use the net proceeds from the offering for various purposes, including funding certain manufacturing, marketing, and research and development activities.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.